EDAP Announces Pricing of Public Offering of American


LYON, France, September 22, 2022 — EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a worldwide chief in robotic energy-based therapies, introduced that the value of its public providing of its American Depositary Shares (“ADSs”), which commenced on September 22, 2022, has been set right now at $7.50 per ADS, earlier than underwriting reductions and commissions, and that the quantity of supplied ADSs is 2,666,667. In addition, Jefferies LLC has been granted a 30-day over-allotment choice to buy as much as a further 400,000 ADSs on the identical phrases and situations. The gross proceeds from the providing, earlier than deducting underwriting reductions and commissions and different providing bills payable by the Company, are anticipated to be roughly $20,000,003. The closing of the providing is predicted to happen on September 27, 2022, topic to customary closing situations.

Jefferies LLC is performing as the only real book-running supervisor for the providing.

A shelf registration assertion on Form F-3 (together with a prospectus) regarding the Company’s American Depositary Shares was filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2021 and is efficient. The Company has additionally filed a base prospectus dated April 16, 2021 and a preliminary prospectus complement dated September 22, 2022 with respect to the providing. A remaining prospectus complement and the accompanying prospectus will probably be filed with the SEC. You could receive these paperwork at no cost by visiting EDGAR on the SEC’s web site at www.sec.gov. Alternatively, when obtainable, a replica of the prospectus complement (and accompanying prospectus) regarding the providing could also be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by phone at +1 (877) 821-7388 or by electronic mail at Prospectus_Department@Jefferies.com.

See also  Radico Khaitan installs Oxygen Generator Plants at government hospitals in 6 districts of UP

This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of these securities in any state or jurisdiction during which such provide, solicitation or sale can be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction. In explicit, no public providing of the ADSs will probably be made in Europe.

Forward-Looking Statements

This press launch comprises forward-looking statements inside the that means of the Private Securities Litigation Reform Act of 1995, together with statements relating to the anticipated closing of the Company’s follow-on providing. Such statements are primarily based on administration’s present expectations and are topic to a quantity of dangers and uncertainties, together with issues not but recognized to us or not at the moment thought-about materials by us, and there will be no assurance that anticipated occasions will happen or that the targets set out will really be achieved. Important components that would trigger precise outcomes to vary materially from the outcomes anticipated within the forward-looking statements embody, however will not be restricted to, uncertainties associated to market situations, satisfaction of the closing situations of the providing, these dangers regarding the providing and others described within the preliminary prospectus complement and specifically within the sections “Forward-Looking Information” and “Risk Factors” and people dangers regarding the Company’s business, that are described within the Company’s filings with the SEC and specifically within the part “Risk Factors” within the Company’s Annual Report on Form 20-F. The Company undertakes no obligation to replace or revise any forward-looking statements as a way to mirror any occasion or circumstance which will come up after the date of this launch, besides as required by regulation.

See also  Orphalan announces publication of results from the CHELATE

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
+33 4 72 15 31 50

Investor Contact
John Fraunces
LifeSci Advisors, LLC


Source link


Please enter your comment!
Please enter your name here